PetCaseFinder

Peer-reviewed veterinary case report

Neuritin1 Cis-Regulatory Elements Enable Gene Expression Preferentially in Retinal Ganglion Cells.

Journal:
Investigative ophthalmology & visual science
Year:
2026
Authors:
Talla, Venu et al.
Affiliation:
Department of Ophthalmology · United States
Species:
rodent

Abstract

PURPOSE: Retinal ganglion cells (RGCs) are essential for visual signal transmission, yet they are vulnerable to injury and degeneration. Gene modulation in RGCs using adeno-associated virus (AAV) offers a promising avenue for neuroprotection and regeneration, but promoters lack sufficient RGC specificity, limiting the precision needed for preclinical studies. This study aims to identify novel promoter-enhancer combinations (PECs) to achieve gene expression preferentially in RGCs. METHODS: We evaluated existing transcriptomic data to identify neuritin 1 (Nrn1) as a gene with highly restricted RGC expression in the retina. Synthetic PECs derived from human and mouse Nrn1 loci were incorporated into AAV2 vectors driving expression of a nuclear-targeted reporter GreenLantern. AAVs were delivered via intravitreal injection into C57BL6/J mice, and transduction efficiency and RGC specificity were evaluated in both young and aged retinas and those subjected to intraorbital optic nerve crush (ONC), using immunohistochemistry and quantitative analysis of RBPMS+ cells. RESULTS: We found that AAV2 with a human Nrn1-PEC drives gene expression in RGCs. Quantitative analysis revealed that over 83% of transduced cells were RBPMS+, indicating robust RGC selectivity and significantly outperforming ubiquitous promoters. Notably, the Nrn1-PEC retained strong and selective transgene expression in RGCs in aged mice and following ONC, demonstrating its resilience under aged and injury conditions. CONCLUSIONS: The Nrn1-PEC enables efficient and injury-resilient gene expression in RGCs, addressing a key limitation in cell-specific targeting. This AAV-incorporated PEC offers a robust platform for evaluating neuroprotective interventions and accelerates the translational development of gene therapies for glaucoma and other optic neuropathies.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication: https://pubmed.ncbi.nlm.nih.gov/41954328/